tiprankstipranks
Trending News
More News >
Aiml Resources Inc. (TSE:AIML)
:AIML

Aiml Resources (AIML) AI Stock Analysis

Compare
12 Followers

Top Page

TS

Aiml Resources

(AIML)

Rating:55Neutral
Price Target:
C$0.00
▼(-100.00%Downside)
AIML Resources exhibits significant financial challenges, reflected in its weak financial performance score, which is the most heavily weighted factor. However, positive technical indicators and strategic corporate events provide some optimism. Despite a poor valuation, the recent strategic initiatives may position the company for potential growth, reflected in a moderate overall score.

Aiml Resources (AIML) vs. iShares MSCI Canada ETF (EWC)

Aiml Resources Business Overview & Revenue Model

Company DescriptionAI/ML Innovations Inc. operates in the digital healthcare business using artificial intelligence (AI) and machine learning (ML). It focuses on offering a patent-pending personal health monitoring and management system for caregivers, patients, and healthcare professionals to access and utilize data for enhance recovery outcomes and healthy living, as well as digital health software and wearable technologies. The company was formerly known as AIML Resources Inc. and changed its name to AI/ML Innovations Inc. in November 2020. AI/ML Innovations Inc. was incorporated in 2009 and is headquartered in Victoria, Canada.
How the Company Makes MoneyAiml Resources generates revenue through a diverse range of income streams. The company's primary source of income is the licensing of its proprietary AI and machine learning software to businesses across different sectors. AIML also offers subscription-based access to its advanced analytics platforms, providing companies with ongoing support and updates. Additionally, the company generates revenue through consulting services, where it offers expertise in AI implementation and strategy development. Partnerships with leading technology firms and industry-specific collaborations further enhance AIML's earnings by expanding its market reach and integrating its solutions into broader digital ecosystems.

Aiml Resources Financial Statement Overview

Summary
Aiml Resources faces significant financial difficulties across all financial statements. The income statement shows persistent losses and declining revenue. The balance sheet is risky due to past negative equity and high liabilities, despite some improvement in equity. Cash flows are consistently negative, indicating ongoing operational and cash management issues.
Income Statement
10
Very Negative
Aiml Resources has shown significant challenges in its income statement metrics. The Gross Profit Margin is negative, indicating a loss on the gross level. The Net Profit Margin is also deeply negative, reflecting substantial net losses. Revenue has decreased from the previous full year, highlighting a revenue growth issue. EBIT and EBITDA margins are negative, further illustrating operational inefficiencies and financial distress.
Balance Sheet
20
Very Negative
The balance sheet reveals a mixed picture with some serious concerns. The company has a negative debt-to-equity ratio due to negative equity in previous years, indicating high leverage risk. Despite this, the recent TTM period shows positive equity, improving stability. The equity ratio is moderate, suggesting some reliance on equity financing. However, the overall financial health remains fragile.
Cash Flow
15
Very Negative
Cash flow analysis indicates persistent negative operating cash flows, suggesting operational struggles. The Free Cash Flow is negative, and the Free Cash Flow to Net Income Ratio is unfavorable. Free Cash Flow growth is not evident, reflecting cash management challenges. While the company has managed some financing cash inflows, it has not resulted in operational cash improvements.
BreakdownTTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue201.21K600.14K487.50K65.41K0.000.00
Gross Profit-91.26K294.86K466.01K65.41K0.000.00
EBITDA-2.65M-1.67M-1.30M-3.44M-1.43M-177.00K
Net Income-4.11M-3.29M-1.42M-3.17M-2.73M-236.00K
Balance Sheet
Total Assets3.36M329.69K1.51M2.04M3.59M319.87K
Cash, Cash Equivalents and Short-Term Investments1.86M216.86K14.56K525.24K3.49M177.17K
Total Debt203.17K197.72K809.37K261.34K320.29K422.00K
Total Liabilities771.53K1.54M1.79M1.55M1.51M2.14M
Stockholders Equity2.62M-1.17M-247.46K1.08M2.31M-1.82M
Cash Flow
Free Cash Flow-2.69M-1.64M-634.28K-3.02M-959.00K-154.72K
Operating Cash Flow-2.69M-1.64M-634.28K-3.02M-931.35K-126.91K
Investing Cash Flow0.00-325.98K-210.64K-1.14M-11.38K-27.80K
Financing Cash Flow4.05M2.16M374.37K1.27M4.17M288.65K

Aiml Resources Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.05
Price Trends
50DMA
0.09
Negative
100DMA
0.08
Negative
200DMA
0.09
Negative
Market Momentum
MACD
-0.01
Positive
RSI
27.33
Positive
STOCH
13.33
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AIML, the sentiment is Negative. The current price of 0.05 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.09, and below the 200-day MA of 0.09, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 27.33 is Positive, neither overbought nor oversold. The STOCH value of 13.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:AIML.

Aiml Resources Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
55
Neutral
C$8.67M-244.35%-71.31%-53.11%
52
Neutral
$7.53B0.32-61.76%2.28%16.60%1.56%
TSADK
46
Neutral
C$20.88M366.78%-39.00%-11.21%
TSCHS
44
Neutral
C$8.43M2.18%-7.15%97.22%
34
Underperform
$13.73M-9999.00%-50.06%
34
Underperform
$28.69M-507.20%-171.18%46.80%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:AIML
Aiml Resources
0.05
-0.05
-50.00%
TSE:ADK
Diagnos
0.20
-0.09
-31.03%
TSE:TRUE
Treatment.com International
0.39
-0.61
-61.11%
TSE:CHS
Comprehensive Healthcare Systems Inc
0.68
0.48
240.00%
TSE:UDOC
UniDoc Health Corp
0.18
-0.65
-78.31%

Aiml Resources Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
AIML Innovations Partners with Circular Health to Enhance ECG Smart Ring
Positive
Jun 3, 2025

AI/ML Innovations Inc.’s subsidiary, Neural Cloud Solutions, has signed a Letter of Intent with Circular Health Limited to license its MaxYield™ ECG signal-processing platform. This collaboration aims to enhance Circular Health’s smart ring with AI-powered ECG signal clarity, targeting a commercial launch by September 2025. The partnership is expected to improve the quality of ECG signals, increase data usability, and provide deeper biometric insights, positioning both companies for global growth in AI-enhanced cardiac monitoring and next-gen health intelligence.

Executive/Board ChangesBusiness Operations and Strategy
AIML Innovations Inc. Forms Innovation Committee to Drive Health-Tech Advancements
Positive
May 22, 2025

AI/ML Innovations Inc. has established an Innovation Committee to enhance its regulatory strategy, intellectual property development, and product innovation within its AI-driven health-tech portfolio. Dr. Drew Dundas, a seasoned expert in medical-device innovation, has been appointed as the Chair of this committee. This strategic move is expected to strengthen AIML’s governance and position the company to deliver sustained value to clinicians, partners, and shareholders by ensuring that its technology has a global clinical impact.

Executive/Board ChangesBusiness Operations and Strategy
AIML Innovations Forms Medical Advisory Board to Propel AI-Driven Cardiac Solutions
Positive
May 20, 2025

AI/ML Innovations Inc. has established a Medical Advisory Board composed of leading cardiovascular experts to guide the clinical studies, regulatory strategy, and global adoption of its AI-driven ECG signal-processing solutions, MaxYield™ and CardioYield™. This strategic move aims to integrate clinical insights into AIML’s operations, enhancing product development and commercialization strategies. The company also launched a redesigned corporate website to serve as an interactive hub for stakeholders. The establishment of the board underscores AIML’s commitment to advancing AI-enhanced cardiac diagnostics and expanding its market presence.

Product-Related AnnouncementsRegulatory Filings and Compliance
AIML Innovations Advances ECG Technology with FDA Submission for MaxYield Platform
Positive
May 15, 2025

AI/ML Innovations Inc. has submitted a 510(k) premarket notification to the U.S. FDA for its MaxYield™ platform, a cloud-native API designed to enhance ECG signal quality across various care settings. This milestone aims to improve ECG signal interpretation by reducing noise and improving waveform clarity, potentially allowing for seamless integration into digital health ecosystems. The submission builds on AIML’s previous FDA Device Master File, which could facilitate future collaborations with device manufacturers. Additionally, AIML has granted 800,000 stock options to certain directors and consultants, reflecting its ongoing commitment to innovation in AI-driven healthcare solutions.

Executive/Board ChangesBusiness Operations and Strategy
AI/ML Innovations Strengthens Board with Strategic Appointment
Positive
May 7, 2025

AI/ML Innovations Inc. has appointed Michael Diamond, a prominent political strategist and public affairs leader, to its Board of Directors. This move is expected to enhance AIML’s strategic capabilities as it seeks to expand its AI-powered health technologies globally. Diamond’s expertise in public policy and business development is anticipated to help AIML navigate complex regulatory environments and form new partnerships, reinforcing the company’s commitment to growth and innovation in the AI healthcare sector.

M&A TransactionsBusiness Operations and Strategy
AI/ML Innovations Restructures Quantum Sciences Acquisition for Strategic Growth
Positive
Apr 25, 2025

AI/ML Innovations Inc. has restructured its acquisition agreement with Quantum Sciences Ltd. to enhance capital efficiency and simplify its revenue structure. The revised terms include a reduction in consideration shares, nullification of previously agreed royalties, and a new revenue-sharing agreement. This restructuring aligns with AIML’s strategic focus on AI-powered health solutions, aiming to streamline operations and concentrate resources on high-growth areas, thereby improving flexibility for future investments and partnerships.

Executive/Board ChangesBusiness Operations and Strategy
AI/ML Innovations Announces Board Change as Tim Daniels Steps Down
Neutral
Apr 25, 2025

AI/ML Innovations Inc. announced the departure of Tim Daniels from its Board of Directors, effective immediately. Daniels, who has been instrumental in guiding the company’s strategic direction and growth, will continue to support AIML in an advisory role. This change is part of AIML’s efforts to strengthen its leadership and advisory network to support its commercialization and strategic growth initiatives in AI-driven healthcare.

Executive/Board ChangesBusiness Operations and Strategy
AI/ML Innovations Strengthens Board with New Appointment
Positive
Apr 22, 2025

AI/ML Innovations Inc. has appointed Jared Adelstein to its Board of Directors as part of its strategic growth and commercialization efforts in the AI-powered healthcare sector. This appointment is expected to enhance the company’s governance and leadership, supporting its mission to deliver innovative AI solutions in healthcare and marking a significant step in its growth trajectory.

Private Placements and FinancingBusiness Operations and Strategy
AI/ML Innovations Closes Oversubscribed Private Placement and Modifies Warrant Terms
Positive
Apr 15, 2025

AI/ML Innovations Inc. has successfully closed an oversubscribed private placement, raising $2,165,900, surpassing its initial target of $2,000,000. The funds will be used for general working capital, and the strong investor participation reflects confidence in the company’s strategic direction. The company also announced modifications to existing warrants, adjusting the exercise price to $0.20, which aligns with its current financial strategies.

Private Placements and Financing
AI/ML Innovations Inc. Announces $2 Million Private Placement Offering
Neutral
Apr 7, 2025

AI/ML Innovations Inc. announced a non-brokered private placement offering of up to 40 million units at $0.05 per unit, aiming to raise $2 million. The proceeds will be used for working capital, with each unit consisting of one common share and one warrant, exercisable into a common share at $0.15 over three years. The private placement is subject to necessary approvals, and finder’s fees will be paid to qualified finders.

Private Placements and FinancingBusiness Operations and Strategy
AI/ML Innovations Inc. Announces $2 Million Private Placement to Strengthen Financial Position
Positive
Apr 4, 2025

AI/ML Innovations Inc. announced a proposed non-brokered private placement offering of up to 40,000,000 units at $0.05 per unit, aiming to raise up to $2,000,000. The proceeds will be used for working capital requirements, and the offering is subject to necessary approvals. This move is expected to bolster the company’s financial position and support its strategic initiatives in the AI and ML sectors.

M&A TransactionsBusiness Operations and Strategy
AI/ML Innovations Inc. Exits Tech2Heal to Focus on Core Digital Health Ventures
Positive
Mar 21, 2025

AI/ML Innovations Inc. has announced its strategic exit from Tech2Heal, a France-based digital health company, to focus on the commercialization of its core holdings. This move allows AIML to realign its resources towards its primary subsidiaries, enhancing its market positioning in digital health innovations. The exit agreement involves relinquishing its equity position and board rights in Tech2Heal in exchange for the return of shares and equity, positioning AIML for future collaborations and growth in its core areas.

Executive/Board ChangesBusiness Operations and Strategy
AI/ML Innovations Inc. Restructures Board for Strategic Growth
Positive
Mar 14, 2025

AI/ML Innovations Inc. has announced significant changes to its Board of Directors to align with its growth and commercialization goals. The appointment of Paul Duffy as Executive Chairman and Peter Kendall to the Board, along with the continued advisory roles of Mark Orsmond and Michael Nemirow, reflects the company’s strategic focus on enhancing its commercialization efforts and driving shareholder value.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 04, 2025